<DOC>
	<DOCNO>NCT01853254</DOCNO>
	<brief_summary>This open-label , non-randomized , single arm study provide treatment re-treatment Pegasys ( peginterferon alfa-2a ) monotherapy combination Copegus ( ribavirin ) patient chronic hepatitis C infection . Patients receive prior Pegasys monotherapy combination therapy consider eligible treatment Pegasys previous donor protocol eligible participate study . Treatment investigator 's decision accord approve label 48 week , 24-week safety follow-up .</brief_summary>
	<brief_title>A Study Pegasys ( Peginterferon Alfa-2a ) Administered Alone Combination With Copegus ( Ribavirin ) Patients With Chronic Hepatitis C Who Have Participated Previous Pegasys Trials</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient , â‰¥ 18 year age . Chronic hepatitis C. Compensated liver disease ( ChildPugh Class A ) . Previous participation donor protocol treatment retreatment Pegasys alone combination Copegus recommend deem appropriate study completion . Have complete safety efficacy assessment define donor protocol without violation major deviation . Have receive antihepatitis C virus treatment completion donor protocol . For female childbearing potential , negative pregnancy test within 24 hour prior first dose study drug . Fertile patient ( male female ) must use 2 reliable form contraception ( combine ) duration study ( treatment followup ) accordance locally approve label Copegus . Pregnant breastfeed woman . Male partner woman pregnant . Patients hemoglobinopathy . Hepatic decompensation ( ChildPugh Class B C ) treatment . Nonresponder patient ( defined patient previously treat Pegasys Copegus combination therapy standard dose least 12 week achieve least 2log drop baseline viral load ) . Liver disease chronic hepatitis C , include hepatic carcinoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>